AbbVie Inc (ABBV)

Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more income a decade from now than a double-digit payout ever could.

AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in ADARx ties AbbVie to RNA-based therapies being developed for certain rare disease indications. Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. AbbVie's move into ADARx's IPO and the new EPKINLY approval both need weighing against the rest of our ABBV thesis. We have...

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

InMode (INMD) stays rangebound as US sales slip; global growth and consumables stabilize. Read here for a detailed investment analysis.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026